Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Yahoo FinanceOct 25 10:00 ET

Arcutis Presents New Patient-Reported Outcome Data For ZORYVE Cream 0.15% In Atopic Dermatitis At American College Of Allergy, Asthma And Immunology 2024 Annual Scientific Meeting

BenzingaOct 24 08:01 ET

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

GlobeNewswireOct 23 16:00 ET

Buy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales Forecast

TipRanksOct 23 04:35 ET · Ratings

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

BenzingaOct 22 07:36 ET

Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

GlobeNewswireOct 18 08:20 ET